FindTrial
Sign In

In the context of the new crown epidemic, the use status, efficacy and safety of prophylactic use of pegylated recombinant human granulocyte stimulating factor in gynecologic cancer patients

In the context of the new crown epidemic, the use status, efficacy and safety of prophylactic use of pegylated recombinant human granulocyte stimulating factor in gynecologic cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095656
Enrollment
Unknown
Registered
2025-01-10
Start date
2022-08-31
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic tumors

Interventions

Gynecologic tumors:None

Sponsors

National Cancer Center/Peking Union Medical College Cancer Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Visits between December 1, 2019 and December 31, 2022; 2.Histopathological diagnosis of gynecological tumor; 3.prophylactic use of PEG-rhG-CSF; 4.Received at least 2 cycles of chemotherapy regimen treatment; 5.WBC =3.0×109/L or ANC=1.5×109/L before the first cycle of chemotherapy; 6.Age = 18 years.

Exclusion criteria

Exclusion criteria: 1.Patients with other primary cancers within the last 5 years; 2. Patients with tumor invasion of bone marrow; 3. Patients who have received whole-body bone radiotherapy within 15 days prior to the first dose of PEG-rhG-CSF; 4. Severely infected people.

Design outcomes

Primary

MeasureTime frame
ANC count;Incidence of FN, risk level;Chemotherapy postponement rate;—

Countries

China

Contacts

Public ContactLi Bin

National Cancer Center/Peking Union Medical College Cancer Hospital, Chinese Academy of Medical Sciences

libin@cicams.ac.cn+86 138 0136 4117

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026